Table 4.
Histopathologic Characteristics of Endometrial Cancer Cases by SERM Use
| Category | Nonusers
|
Raloxifene
|
Tamoxifen
|
P | |||
|---|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | ||
| Histologic type | |||||||
| Adenocarcinoma | 467 | 94 | 18 | 100 | 26 | 76 | < .001 |
| Papillary-serous or clear cell | 28 | 6 | 0 | 0 | 8 | 24 | |
| Total | 495 | 18 | 34 | ||||
| FIGO stage*† | |||||||
| I | 363 | 83 | 16 | 94 | 22 | 76 | .53‡ |
| II | 35 | 8 | 0 | 0 | 4 | 14 | |
| III | 27 | 6 | 1 | 6 | 3 | 10 | |
| IV | 13 | 3 | 0 | 0 | 0 | 0 | |
| Total | 438 | 17 | 29 | ||||
| Histologic grade*§ | |||||||
| 1 | 214 | 46 | 12 | 67 | 16 | 52 | .21‖ |
| 2 | 155 | 33 | 4 | 22 | 6 | 19 | |
| 3 | 97 | 21 | 2 | 11 | 9 | 29 | |
| Total | 466 | 18 | 31 | ||||
Abbreviations: SERM, selective estrogen receptor modulator; FIGO, International Federation of Gynecology and Obstetrics.
*
Among all histologic types.
†
Sixty-three cases are missing FIGO stage.
‡
P = .28 for association of FIGO stages I/II+ with SERM use.
§
Thirty-two cases are missing histologic grade.
‖
P = .19 for association of grades 1/2+ with SERM use.